Clinical Validation of AI-Powered PD-L1 Tumor Proportion Score Interpretation for Predicting Immune Checkpoint Inhibitor Response in NSCLC

Clinical Validation of AI-based Interpretation of PD-L1 Tumor Proportion Score in Predicting Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer In the field of tumor treatment and diagnosis, the assessment of PD-L1 (Programmed Death-Ligand 1) Tumor Proportion Score (TPS) is a critical task, especially in predicting the response ...

Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients with Newly Diagnosed Prostate Cancer

Using Cell Cycle Risk Score to Predict the Benefit of Radiotherapy Combined with ADT in Newly Diagnosed Prostate Cancer Patients Background Prostate cancer is one of the most common cancers among men globally. In terms of treatment, localized prostate cancer is often treated primarily with radiotherapy (RT). However, the efficacy of RT alone is oft...

Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients with Advanced Prostate Cancer from Latin America: Challenges and Future Approaches

Academic Report for the Paper Titled “Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients with Advanced Prostate Cancer from Latin America: Challenges and Future Approaches” Background Prostate cancer is one of the most common cancers among men in Latin America and the Caribbean (LAC). According to the 2020 Glo...

Quantitative Integrative Survival Prediction in Multiple Myeloma Patients

Precision Medicine | Quantitative Comprehensive Survival Prediction for Patients with Multiple Myeloma: Based on Bortezomib Induction Therapy, High-Dose Treatment, and Autologous Stem Cell Transplantation Introduction Multiple myeloma is a malignant hematological disease characterized by the accumulation of clonal plasma cells within the bone marro...

Clonal Hematopoiesis in Patients with Neuroendocrine Tumor Treated with Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study

Clonal Hematopoiesis in Patients with Neuroendocrine Tumor Treated with Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study

Clonal Hematopoiesis and Risk of Thrombocytopenia in Neuroendocrine Tumor Patients Undergoing 177Lu Therapy: A Prospective Study Background and Research Motivation The incidence of Neuroendocrine Tumors (NETs) has gradually increased in recent years. Prognosis depends on various factors such as the location of the primary tumor, disease grading, st...

Association of Timely Comprehensive Genomic Profiling with Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer

Association of Timely Comprehensive Genomic Profiling with Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer

Study on the Association Between the Timeliness of Comprehensive Genomic Profiling in Precision Oncology and Treatment Choices and Outcomes for Patients with Advanced Non-Small Cell Lung Cancer Introduction Advanced non-small-cell lung cancer (ANSCLC) is a highly lethal malignancy, and treatment choices directly affect the overall survival rate of ...

Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer

Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer

Background of Urgent Problem Prostate cancer is one of the most common cancers among men. Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer characterized by resistance to castration therapy. Radium-223 is an α-emitting radiopharmaceutical that has been shown to improve overall survival (OS) and reduce sk...

Comprehensive Genomic Analysis of Patients with Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings from the BFAST Database of a Single Center in Taiwan

Latest Research in Lung Cancer Genomics: Analysis of Circulating Tumor DNA Detection in Non-Small Cell Lung Cancer Background and Motivation In recent years, the treatment of non-small cell lung cancer (NSCLC) has seen significant changes due to the success of targeted therapies. The National Comprehensive Cancer Network guidelines recommend extens...

Pan-Cancer Interrogation of MUTYH Variants Reveals Biallelic Inactivation and Defective Base Excision Repair Across a Spectrum of Solid Tumors

Cross-Cancer Study Reveals Biallelic Inactivation of MUTYH and Base Excision Repair Defects in Different Types of Solid Tumors Research Background In daily life, cells are often exposed to endogenous and exogenous oxidative stress, originating from by-products of cellular respiration and various external compounds. MUTYH is a key component of the b...

Hereditary Cancer Screening and Outcomes at an Urban Safety-Net Hospital

Screening and Outcomes of Hereditary Cancer Syndromes: A Study at an Urban Safety Net Hospital Study Background Patients with Hereditary Cancer Syndromes (HCS) have a higher lifetime risk of developing cancer. Historically, underserved populations have lower rates of genetic evaluation. Hence, researchers aim to understand the demographic factors i...